卡麦角林与羟氯喹预防多囊卵巢综合征（PCOS）患者卵巢过度刺激综合征（OHSS）的比较研究：一项前瞻性随机临床试验
Comparative study of cabergoline and hydroxychloroquine to prevent ovarian hyperstimulation syndrome (OHSS) in PCOS patients: a pilot randomized clinical trial.
作者信息
Salari Elnaz, Ajabi Ardehjani Negar, Kashani Ladan, Jafari Kasra, Moini Ashraf
机构信息
Department of Obstetrics and Gynecology, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Department of Anatomical Sciences, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
出版信息
J Ovarian Res. 2025 May 29;18(1):113. doi: 10.1186/s13048-025-01702-6.
BACKGROUND
This study compared the effectiveness of cabergoline and hydroxychloroquine in preventing ovarian hyperstimulation syndrome (OHSS) in patients with polycystic ovary syndrome (PCOS) undergoing controlled ovarian stimulation.
MATERIALS AND METHODS
This double-blind, parallel, and randomized clinical trial was performed from April to June 2024. Forty-two patients with PCOS who were candidates for assisted reproductive techniques were randomized into two groups. The first group received 0.5 mg of cabergoline, and the second group received 400 mg of hydroxychloroquine for 8 days. Then, ultrasounds were conducted on days 3 and 5 after oocyte retrieval to assess for OHSS.
RESULTS
Three and five days after oocyte retrieval, laboratory findings, and clinical outcomes were similar between the cabergoline and hydroxychloroquine groups. Key laboratory parameters, including hemoglobin, hematocrit, sodium, potassium, blood urea nitrogen, and creatinine, did not show significant differences between the groups. On day three, OHSS incidence didn't have a significant difference between the hydroxychloroquine and cabergoline groups, both for the mild (31.58% vs. 42.86%) and moderate (15.79% vs. 9.52%) groups. Mild cases were observed in one of the patients in both groups 5 days after pickup (p = 0.942). No patients in the cabergoline group required hospitalization or treatment, compared to one in the hydroxychloroquine group (p = 0.127).
CONCLUSION
The incidence of OHSS was similar between cabergoline and hydroxychloroquine, with no significant differences observed in laboratory parameters or clinical outcomes after oocyte retrieval. However, given the study's sample size, further research is needed before these findings can be generalized to a larger population.
CLINICAL TRIAL NUMBER
http://www.irct.ir ; Registration number: IRCT20240305061171N1; Registration date: 2024 June 29.
背景
本研究比较了卡麦角林和羟氯喹预防接受控制性卵巢刺激的多囊卵巢综合征（PCOS）患者发生卵巢过度刺激综合征（OHSS）的有效性。
材料与方法
本双盲、平行、随机临床试验于2024年4月至6月进行。42例有辅助生殖技术指征的PCOS患者被随机分为两组。第一组接受0.5毫克卡麦角林，第二组接受400毫克羟氯喹，持续8天。然后，在取卵后第3天和第5天进行超声检查以评估OHSS。
结果
取卵后第3天和第5天，卡麦角林组和羟氯喹组的实验室检查结果和临床结局相似。关键实验室参数，包括血红蛋白、血细胞比容、钠、钾、血尿素氮和肌酐，两组之间无显著差异。第3天，羟氯喹组和卡麦角林组的OHSS发生率在轻度（31.58%对42.86%）和中度（15.79%对9.52%）组之间均无显著差异。取卵后5天，两组各有1例患者出现轻度病例（p = 0.942）。卡麦角林组无患者需要住院或治疗，羟氯喹组有1例（p = 0.127）。
结论
卡麦角林和羟氯喹的OHSS发生率相似，取卵后实验室参数或临床结局无显著差异。然而，鉴于本研究的样本量，在这些结果能够推广到更大人群之前，还需要进一步研究。
临床试验编号
http://www.irct.ir ；注册号：IRCT20240305061171N1；注册日期：2024年6月29日。
Zotero 插件